Sponsored Videos

Ajay Damani, President of Coating Place, discusses the impact of the current CDMO landscape on oral solid dose pharmaceuticals.

The evolution of Pace® Life Sciences from an analytical services firm to a full-service CDMO supporting the drug development lifecycle.

Discover how Piramal Pharma Solutions is innovating in integrated CDMO services, leveraging their Science Collective of experts to streamline drug substance and drug product programs from early development through commercialization.

Emily Schirmer, Catalent, explains how to accelerate the path to first-in-human trials as biologics pipelines grow more complex and timelines tighten.

Christian Houborg discusses how FUJIFILM Biotechnologies is helping customers navigate evolving patient demand and supply chain uncertainty.

The CDMO landscape is shifting toward long-term strategic partnerships as drug modalities grow more complex and supply chain pressures mount. Noritsugu Fujita, Division President of Pharmaceutical Solutions Division at Terumo, explains how an integrated, single-source model for parenteral drug development aims to streamline the path to a patient-ready product.

Peter Belden, Tjoapack, discusses how the rise of specialized medicines for smaller patient populations is necessitating more flexible, redundant packaging capacity to manage complex global distribution requirements.

Paul Smaltz, Senior Vice President of BASF Pharma Solutions, explains how the company acts as a strategic partner to the pharmaceutical industry by integrating AI-driven formulation tools, sustainability initiatives, and specialized biopharmaceutical solutions to overcome modern manufacturing challenges.

Joerg Ahlgrimm, CEO of SK pharmteco, outlines the company's strategic expansion into cell and gene therapy. He also details their commitment to global operational excellence and a culture of employee purpose.

Terry Novak, CEO of Benuvia, explores how pharmaceutical and biotech companies can mitigate development risks and accelerate speed-to-market by prioritizing technical alignment, robust project management, and early-stage collaboration with the right CDMO partner.

Hear from Miguel Ángel Ortega Sánchez, Corporate Industrial Director at ROIS CDMO, as he breaks down the company’s new brand, a strategic acquisition, and what these moves mean for ROIS’s future as a global leader in high-value injectables.

LabVantage is advancing software as a service (SaaS) for the laboratory information management system (LIMS) market to provide laboratories with reduced costs and pre-validated solutions that facilitate scalability and faster speed-to-market for pharmaceuticals

Nina Moreno, Nelson Labs, explains how rapid sterility testing is reshaping pharmaceutical quality control—cutting release times, improving objectivity, and gaining regulatory momentum.

Mandy Vink, VP of Business Development at Codexis, explains how the company leverages over 20 years of expertise in small molecule APIs to advance biocatalysis across pharma.

Britton Jimenez, SVP of Sales and Marketing at Codexis, explains how the ECO Synthesis® Manufacturing Platform overcomes the limitations in scalability and sustainability that currently challenge the RNA therapeutics industry.

A long-term, trust-based CDMO partnership can support cell and gene therapy developers from early process development through GMP manufacturing and commercial supply.

Jonathan Haigh, Head of UK Sites, FUJIFILM Biotechnologies, explores how advanced technologies are being used to reduce risk and strengthen global supply chains for biologics.

Biopharmaceutical manufacturers can strategically choose between fed-batch and continuous manufacturing to balance scalability, flexibility, and market demand across the product lifecycle.

The biannual AustinPx Amorphous Solid Dispersions (ASD) Workshop is a place for collaboration and innovation. Hear firsthand from attendees about challenges and insights from the front lines of amorphous drug development.

Watch this interview and learn how advances in patient-centric drug delivery are transforming ten23 health's development strategies as a next-generation CDMO.

In this interview, Sandra Reid of gChem explains how PROCIPIENT®, its USP-grade DMSO, is uniquely manufactured under cGMP and ICH Q7 guidelines to ensure compliance, consistency, and quality across global pharmaceutical markets.

In this interview, Rishi Pimentel of gChem explains how PROCIPIENT®, a cGMP-compliant excipient-grade DMSO, supports advanced therapies with superior purity and sterility, mitigates risks of using industrial-grade solvents, and strengthens regulatory readiness and supply chain security.

In this interview, Dr Nigel Langley of gChem discusses the importance of excipient grade, compliance, and supply chain transparency, and introduces PROCIPIENT®, gChem’s high-purity pharmaceutical-grade DMSO.

David McErlane, Group President of Biologics at Catalent, shares how integrated expertise in biologics helps simplify complexity, accelerate development, and deliver therapies to patients faster.

Saleem Farooqui of Fresenius Kabi explains how the company is addressing today’s pharmaceutical manufacturing needs. Watch this video to learn how these capabilities can help bring products to market successfully.

How Techceuticals, PharmParts, and smart auction strategies are ushering in a new era of efficiency and innovation for CDMOs

Peter DeYoung, CEO at Piramal Pharma Limited, explains how Piramal is meeting the growing demand for integrated biologics manufacturing by expanding capabilities and expertise.

Dave Wood, CEO at Experic, discusses how decades of expertise with advanced technologies helps pharmaceutical and biotech partners bring products to market faster.